The FDA has placed its most serious warning - called a Boxed Warning - on the non-hormonal drug fezolinetant, which is sold under the brand name Veozah.

Veozah was approved in 2023. It works without hormones to reduce hot flashes by blocking a receptor called neurokinin B, which plays a role in the brain’s regulation of body temperature.

Astellas is currently pitching peak sales guidance of 300 billion yen ($2.2 billion) to 500 billion yen per year for Veozah, which could go a long way to ease the pain of patent losses to its ...

“And it's part of why I felt so strongly about talking about Veozah. So many people don’t know about it. It’s a completely, 100% hormone-free option that could be right for some women.” ...

Elinzanetant works similarly to Veozah, targeting a receptor known as neurokinin 3, as well as another dubbed neurokinin 1. Both receptors are involved in regulating body temperature.

Astellas’ drug, Veozah, uses a new approach, targeting brain connections that help control body temperature. The FDA said the medication will provide “an additional safe and effective ...

July 25 (Reuters) - The U.S. Food and Drug Administration has extended its review of Bayer's (BAYGn.DE), opens new tab experimental menopause relief drug, the German company said on Friday. The ...

Astellas’ drug, Veozah, uses a new approach, targeting brain connections that help control body temperature. The FDA said the medication will provide “an additional safe and effective ...